RCUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Mar. 2024, Arcus Biosciences spent $4.0 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $387.0 Mil on purchasing investments. It gained $222.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, Arcus Biosciences spent $169.0 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.
The historical data trend for Arcus Biosciences's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Flow from Investing | Get a 7-Day Free Trial | 59.21 | -434.00 | -4.00 | -413.00 | 194.00 |
Arcus Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Investing | Get a 7-Day Free Trial | 129.00 | 26.00 | 11.00 | 28.00 | -169.00 |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Arcus Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:
Arcus Biosciences's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-104.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences (NYSE:RCUS) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Arcus Biosciences's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-4.0 Mil. It means Arcus Biosciences spent $4.0 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Arcus Biosciences's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.0 Mil. It means Arcus Biosciences gained $0.0 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Arcus Biosciences's purchase of business for the three months ended in Mar. 2024 was $0.0 Mil. It means Arcus Biosciences spent $0.0 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Arcus Biosciences's sale of business for the three months ended in Mar. 2024 was $0.0 Mil. It means Arcus Biosciences gained $0.0 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Arcus Biosciences's purchase of investment for the three months ended in Mar. 2024 was $-387.0 Mil. It means Arcus Biosciences spent {stock_data.stock.currency_symbol}}387.0 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Arcus Biosciences's sale of investment for the three months ended in Mar. 2024 was $222.0 Mil. It means Arcus Biosciences gained $222.0 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Arcus Biosciences's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.0 Mil. It means Arcus Biosciences paid $0.0 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Arcus Biosciences's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.0 Mil. It means Arcus Biosciences paid $0.0 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Arcus Biosciences's cash from other investing activities for the three months ended in Mar. 2024 was $0.0 Mil. It means Arcus Biosciences paid $0.0 Mil for other investing activities.
Thank you for viewing the detailed overview of Arcus Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Goeltz Ii Robert C. | officer: Chief Financial Officer | 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080 |
Juan C. Jaen | director, 10 percent owner, officer: President | 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Jennifer Jarrett | officer: See Remarks | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Alexander Azoy | officer: Chief Accounting Officer | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Terry J Rosen | director, 10 percent owner, officer: Chief Executive Officer | C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080 |
Carolyn C. Tang | officer: General Counsel | 3928 POINT EDEN WAY, HAYWARD CA 94545 |
Dimitry Sa Nuyten | officer: Chief Medical Officer | 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710 |
Linda Slanec Higgins | director | 3610 LOUIS RD., PALO ALTO CA 94303 |
Nicole Lambert | director | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
William Grossman | officer: Chief Medical Officer | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Yasunori Kaneko | director, 10 percent owner | 509 ROEHAMPTON, HILLS BOROUGH CA 94010 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Michael Quigley | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew J Perlman | director | 618 MIRADA AVE, STANFORD CA 94305 |
From GuruFocus
By Business Wire • 08-09-2023
By Business Wire • 12-04-2023
By Business Wire • 07-11-2023
By Business Wire Business Wire • 05-24-2023
By Business Wire • 08-24-2023
By Business Wire Business Wire • 06-09-2023
By Business Wire • 10-10-2023
By Business Wire Business Wire • 05-15-2023
By Business Wire Business Wire • 06-03-2023
By Business Wire • 08-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.